Confronting America’s Smoking Pandemic, Part 2: 1967–1985

Slideshow

Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 2 highlights the rise of tobacco awareness, and anti-smoking activism and legislation.

Confronting America’s Smoking PandemicPart 1: From Early Evidence to Global Battle, 1939–1966Part 2: An Era of Activism, 1967–1985Part 3: Regulation, Legislation, Litigation, 1986–1999Part 4: Failures and Successes 2000–2016

References:

1. Center for the Study of Tobacco and Society. Robert Kennedy speaks at the 1967 World Conference on Smoking and Health. Video. 1967. Published to YouTube on October 1, 2014.

2. American Cancer Society. History of the Great American Smokeout event.

3. US Department of Health and Human Services. Centers for Disease Control and Prevention (US). The health consequences of smoking-50 years of progress. A report of the Surgeon General. Atlanta, GA: National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health; 2014.

4. Berlyne D. Clearing the air: an overview of smoke-free air laws. RWJF Retrospective Series. Princeton, NJ: Robert Wood Johnson Foundation; April 2011.

5. US Legal, Inc. Smoking regulations in California.

6. SourceWatch. Doctors ought to care.

7. US Public Health Service. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. 4. Nicotine addiction: past and present.

8. US Department of Health Education and Welfare (DHEW), Public Health Service (PHS). Smoking and health: a report of the Surgeon General. DHEW publication no. (PHS) 79-50066. 1979.

9. American College of Chest Physicians. History of ACCP antitobacco activity. Updated June 2010.

10. Neuman MD, Bitton A, Glantz SA. Tobacco industry influence on the definition of tobacco related disorders by the American Tobacco Association. Tobacco Control. 2005;14:328-37.

11. National Library of Medicine. Profiles in Science. The C. Everett Koop Papers: tobacco, second-hand smoke, and the campaign for a smoke-free America.

12. National Cancer Institute. Division of Cancer Prevention Oral History Project: Interview with Peter Greenwald. Conducted on December 4, 2008, by Victoria Harden. Produced by History Associates Incorporated, Rockville, MD.

13. Death in the West. 1976. Film. Thames Television, UK.

14. National Institutes of Health, Centers for Disease Control and Prevention. Use of FDA-approved pharmacologic treatments for tobacco dependence-United States, 1984–1998. MMWR July 28, 2000.

15. US Department of Health and Human Services, US Food and Drug Administration. FDA approves novel medication for smoking cessation. FDA news release P06-67. May 11, 2006.

16. US Department of Health and Human Services. US Food and Drug Administration. FDA: Boxed warning on serious mental health events to be required for Chantix and Zyban. FDA news release. July 1, 2009.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content